Mamitaro Ohtsuki
- Immunology top 0.5%
- Dermatology top 0.05%
- Physiology top 2%
- Molecular Biology top 10%
- Rheumatology top 1%
- Co-authors
- Mayumi KomineJitlada MeephansanKoji KamiyaHidemi NakagawaMegumi KishimotoJunichi SugaiKim PappAndrew Blauvelt
- Topics
- Psoriasis: Treatment and Pathogenesis (88 papers)Dermatology and Skin Diseases (55 papers)Autoimmune Bullous Skin Diseases (27 papers)
- Partner nations
- JapanUnited StatesGermany
In The Last Decade
Mamitaro Ohtsuki
169 papers receiving 6.6k citations
Hit Papers
Peers
Comparison fields: 5 of 134
- Immunology 3.8k
- Dermatology 3.4k
- Physiology 906
- Molecular Biology 900
- Rheumatology 821
Countries citing papers authored by Mamitaro Ohtsuki
This map shows the geographic impact of Mamitaro Ohtsuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mamitaro Ohtsuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mamitaro Ohtsuki more than expected).
Fields of papers citing papers by Mamitaro Ohtsuki
This network shows the impact of papers produced by Mamitaro Ohtsuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mamitaro Ohtsuki. The network helps show where Mamitaro Ohtsuki may publish in the future.
Co-authorship network of co-authors of Mamitaro Ohtsuki
This figure shows the co-authorship network connecting the top 25 collaborators of Mamitaro Ohtsuki. A scholar is included among the top collaborators of Mamitaro Ohtsuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mamitaro Ohtsuki. Mamitaro Ohtsuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 5 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 3 | |
| 6 | 6 | |
| 7 | 3 | |
| 8 | 30 | |
| 9 | 9 | |
| 10 | 4 | |
| 11 | 6 | |
| 12 | 5 | |
| 13 | 24 | |
| 14 | 79 | |
| 15 | EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS | 10 |
| 16 | 11 | |
| 17 | 77 | |
| 18 | 3 | |
| 19 | 1 | |
| 20 | A Consensus Conference Report on Psoriasis Therapy with Cyclosporine MEPC | 7 |
About Mamitaro Ohtsuki
Mamitaro Ohtsuki is a scholar working on Dermatology, Immunology and Immunology and Allergy, having authored 186 papers that have together received 6.8k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (88 papers), Dermatology and Skin Diseases (55 papers) and Autoimmune Bullous Skin Diseases (27 papers). The work is most often cited by research in Dermatology (3.4k citations), Immunology (3.8k citations) and Immunology and Allergy (447 citations). Mamitaro Ohtsuki has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Mayumi Komine, Jitlada Meephansan, Koji Kamiya, Hidemi Nakagawa, Megumi Kishimoto, Junichi Sugai, Kim Papp, Andrew Blauvelt, Miroslav Blumenberg and Md Razib Hossain. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.